Astellas Pharma has struck a drug discovery deal worth up to $100 million per target with X-Chem.
Nonprofit Parkinson’s UK has teamed up with the University of Sheffield to create a virtual biotech.
Bioversys has enlisted Aptuit to support its efforts to identify and validate novel targets and drugs against Gram-negative bacteria.
As Donald Trump is sworn into office today, we look at what the next 100 days and indeed the next four years could mean for the biopharma industry through his…
Evotec and MaRS Innovation have joined forces to found Fibrocor Therapeutics, a fibrotic disease startup.
It’s the time of year for editors to look ahead and attempt to predict, based on the patterns of the past 12 months, what the next trip around the sun will…
Neurimmune and TVM Capital Life Science have partnered to create and fund a single-asset biotech focused on amyotrophic lateral sclerosis.
An audible sigh of relief was heard this morning that, at last, the U.S. 2016 election is over. In the end, in what was an oft-controversial, hot-tempered and…
After a 13-year run at FierceBiotech, I’m stepping aside as editor-in-chief of our plucky, global band of life sciences reporters.
Ipsen has strengthened its connection to Oncodesign, the French oncology specialist that lists Bristol-Myers Squibb among its partners.